uniQure stock rating maintained at Outperform by Mizuho with $30 price target

uniQure (NASDAQ:QURE) reported highly positive three-year Phase 1/2 trial results for its Huntington’s Disease gene therapy, AMT-130, demonstrating a 75% slowing of disease progression against external controls and strong safety. This definitive clinical success has propelled the stock over 220% in the past week, prompting multiple analyst price target increases, including Mizuho to $60 and Leerink Partners to $68. The company plans a Biologics License Application in Q1 2026 and has launched a $200 million public offering to capitalize on this significant progress and fund future development.

Analysis

uniQure (QURE) has reported highly significant positive data from its Phase 1/2 trial of AMT-130, a gene therapy for Huntington’s Disease. The three-year follow-up data demonstrated statistically significant results on primary endpoints, with a high-dose cohort showing a 75% delta in disease progression compared to external controls, substantially exceeding market expectations of approximately 50%. The therapy's strong safety profile, being well-tolerated with no treatment-emergent adverse events since December 2022, further de-risks the asset. This clinical success has catalyzed a major market re-rating, with the stock surging over 220% in the past week. Sell-side analysts have responded bullishly, with Mizuho doubling its price target to $60 and Leerink Partners raising its target to $68, citing the results as a "definitive win." The company has established a clear regulatory path, planning a Biologics License Application (BLA) submission in Q1 2026 for a potential H2 2026 launch. To fund these upcoming milestones, uniQure has initiated a $200 million public offering, capitalizing on its elevated stock price and strong investor sentiment.

Key Decisions for Investors

• The positive Phase 1/2 data significantly de-risks the AMT-130 asset and provides a clear catalyst pathway toward a BLA submission in Q1 2026, creating a compelling long-term thesis for investors with a tolerance for clinical-stage biotech risk.
• Investors should consider the dilutive impact of the newly announced $200 million public share offering, which, while strengthening the balance sheet for pivotal activities, will increase the total share count and may create short-term price pressure.
• Following the stock's 220% surge, it is crucial to re-evaluate the company's valuation relative to the execution risks associated with the regulatory approval process and the commercial launch projected for the second half of 2026.